Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'll bet'cha they paid Bookbinder with pre R/S shares. tee hee..
1000 hrs. this clown gets $155,000 and 3.2 million shares. At todays prices, more or less, $200/hr. My question is: Why did they throw the kitchen sink at this to make it go away.
DNAPrint changes symbol, gets sued: Yesterday, DNAPrint genomics, the genomics research and development company based in Sarasota, announced that as of today, its stock ticker symbol will official change from “DNAP” to “DNAG.” The symbol change is the result of the company’s recent stock consolidation. In other DNAPrint news, the company recently received a lawsuit with some pretty ugly claims against its top executives. The plaintiff, a Montana resident named Lonnie Bookbinder, alleges breach of contract, fraud, and conspiracy, among other claims, against the company, its CEO Richard Gabriel, its Chairman and Chief Medical Officer Hector Gomez, and a now-defunct company called Genbiomics. In the most simple terms, Bookbinder claims that the defendants essentially tricked Bookbinder into doing more than a thousand hours of consulting work for DNAPrint without compensating him properly as promised. The lawsuit was filed by attorney John Chapman of the Sarasota law firm Norton Hammersley Lopez and Skokos.
http://209.85.165.104/search?q=cache:GY1RydjOKGYJ:www.s2report.com/reports/072005/07122005.html+GABR...
On July 8, 2005
The complaint sought
damages arising out of services Mr. Bookbinder claims to have provided on our
behalf. We deny any liability to Mr. Bookbinder. We filed and prevailed on a
Motion to Dismiss the complaint because we believed it did not state a claim.
Plaintiff then filed an Amended Complaint. We have a Motion to Dismiss pending
on the same grounds as that previously filed. If our Motion to Dismiss is
unsuccessful, we intend to defend the litigation vigorously.
http://209.85.165.104/search?q=cache:9O9jwCRKjrQJ:sec.edgar-online.com/2006/05/15/0001231742-06-0003...
Executive Indemnification is in standard contracts
http://209.85.165.104/search?q=cache:lLiKseqdKDAJ:contracts.onecle.com/critical/reinhold.emp.2001.05...
Executive Indemnification post Sarbanes-Oxeley for accounting practices, is a different story. RIBBITT...
DNAPRINT GENOMICS INC (DNAG)
Form: 10QSB
Filing Date: 11/13/2006
Both parties agreed to mediate, and a mediation took place on September 8, 2006. The case was resolved for $115,000 of cash and 1.5 million shares of our common stock.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4757816&Type=HTML
Latest s-8
A. Lonnie L. Bookbinder hereby acknowledges receipt of $50,000 and 1.5 million restricted shares of DNAPrint Genomics, Inc., paid and issued in accordance with the Settlement Agreement and Release referenced above.
B. In lieu of the remaining payment due under the Settlement Agreement and Release of $65,000, Lonnie L. Bookbinder agrees to accept, and DNAPrint Genomics, Inc. agrees to pay to Lonnie L. Bookbinder, the amount of $40,000 on or before February 20, 2007 and, pursuant to an S8 filing, issue to Lonnie L. Bookbinder 2.7 million shares of DNAPrint Genomics, Inc.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4973858&Type=HTML
Dr., the original settlement was for $115,000 and 1.5 million shares. As of Dec. 2006 Dnaprint stated they were in discovery phase and planned on defending this litigation vigorously. Dnaprint has now not only given $115,000 and 1.5 million shares...but have settled to give and additional $40,000 and 2.7 million shares on or before Feb. 20th. Why did they have to make this happen?
Frog, you seem like and intelligent amphibian. You have two days to buy in.
The facts, Dr., are... they're clearing their books of previous legal obligations. And seemingly need to do this by Feb. 20th. hmmmm...
Lonnie L. Bookbinder hereby acknowledges receipt of $50,000 and 1.5 million restricted shares of DNAPrint Genomics, Inc., paid and issued in accordance with the Settlement Agreement and Release referenced above.
B. In lieu of the remaining payment due under the Settlement Agreement and Release of $65,000, Lonnie L. Bookbinder agrees to accept, and DNAPrint Genomics, Inc. agrees to pay to Lonnie L. Bookbinder, the amount of $40,000 on or before February 20, 2007 and, pursuant to an S8 filing, issue to Lonnie L. Bookbinder 2.7 million shares of DNAPrint Genomics, Inc.
C. Lonnie L. Bookbinder agrees to accept the above cash payments and stock shares in full, complete, absolute and final settlement of all claims whether known or unknown,
Jever, what I found interesting about Inovio is they are still losing money but have serious partnerships. Inovio market cap is about 100 million.
Our outstanding, as of today is around 400 million. With serious partnerships do you think we might see .25c
If ADMIXMAP is the platform, we'll be getting some serious royalties!!
Nice find Stocky!!! Under the agreements, Moffitt pays the affiliates so that they can hire additional staff to process the tissues and paperwork for samples that will be sent to Moffitt for inclusion in the databank.
Patents and Pharmacogenomics:
http://www.ipfrontline.com/downloads/pharmacogenomics.pdf
stock,
What will our price be when the conversion takes place is the question. I suspect that big 80,000,000 share trading day before the Statnome news was Dutchess covering their short positions.
In order to continue to use our $35 million funding facility with Dutchess
Equity Partners to fund our operations and complete future acquisitions, during
April 2006 we filed a registration statement to register 600,000,000 shares of
our common stock for this facility. The registration statement was declared
effective on May 1, 2006. On September 14, 2006, we filed a registration
statement to register 260,281,228 shares of our common stock of which
175,000,000 shares were for the shares underlying the convertible debentures
held by Dutchess and 45,000,000 shares were for the shares underlying the
convertible debentures held by La Jolla. The SEC is in the process of reviewing
this filing.
The Dutchess Agreement provides that we from time to time may deliver a notice
to Dutchess that will state the dollar amount of common stock that we desire it
to purchase. The maximum amount permitted pursuant to any such notice is
$600,000, and we can give approximately three such notices per month. Upon
receipt of the notice, Dutchess is obliged to purchase the dollar amount of
common stock set forth in the notice at a purchase price equal to 96% of the
average of the two lowest closing bid prices of the common stock during the five
trading days after the notice. We are not permitted to provide a notice to
Dutchess, and Duchess is not obliged to purchase any of our shares, in the event
that we do not have sufficient authorized shares available for purchase to
fulfill such commitment. In accordance with the outstanding notes we issued to
Dutchess, we are required to use 100% of the proceeds from these puts as payment
on the notes.
4/25/06: SEC to issue effectiveness order electronically
At long last, the SEC has announced that it will issue effectiveness orders on registration statements electronically, rather than mailing the orders as is currently the SEC's practice, often several months after the fact. On May 22, 2006, the staffs of the Divisions of Corporation Finance and Investment Management will begin to use the EDGAR system to issue notifications of effectiveness for Securities Act registration statements and post-effective amendments, other than those that become effective automatically by law (e.g., WKSI s-3S, all S-8s et al). These notifications will be posted to the EDGAR system the morning after a filing is determined to be effective.
BEN
EFFECT filings are notice's of effectiveness of POS AM's and some S filings ie: S-1, SB-2. The EFFECT filing comes prior to the 424B3 filing we see when the shares enter the market.
We continue to fund our operations and research and development through the
notes payable proceeds we receive from Dutchess. On March 6, 2006, we issued to
Dutchess a promissory note in the amount of $1,500,000 for a purchase price of
$1,200,000. The note is due and payable in full on March 6, 2007. Other than the
$300,000 discount inherent in the purchase price, the note is
non-interest-bearing. The note will be repaid using the proceeds of each put
notice delivered by us to Dutchess under the September 2004 Investment
Agreement.
38
<PAGE>
On April 17, 2006, we issued to Dutchess a promissory note in the amount of
$1,470,000 for a purchase price of $1,175,000. The note is due and payable in
full on April 17, 2007. Other than the $295,000 discount inherent in the
purchase price, the note is non-interest-bearing. The note will be repaid using
the proceeds of each put notice delivered by us to Dutchess under the September
2004 Investment Agreement.
On May 18, 2006, we issued to Dutchess a promissory note in the amount of
$1,300,000 for a purchase price of $1,000,000. The note is due and payable in
full on May 18, 2007. Other than the $300,000 discount inherent in the purchase
price, the note is non-interest-bearing. The note will be repaid using the
proceeds of each put notice delivered by us to Dutchess under the September 2004
Investment Agreement.
On June 30, 2006, we issued to Dutchess a promissory note in the amount of
$1,495,000 for a purchase price of $1,150,000. The note is due and payable in
full on June 29, 2007. Other than the $345,000 discount inherent in the purchase
price, the note is non-interest-bearing. The note will be repaid using the
proceeds of each put notice delivered by us to Dutchess under the September 2004
Investment Agreement
In connection with the notes, we paid Dutchess facility fees of $310,000 and
convertible debentures totaling $1,353,750. We also paid approximately $181,000
of fees to Athena.
In order to continue to use our $35 million funding facility with Dutchess
Equity Partners to fund our operations and complete future acquisitions, during
April 2006 we filed a registration statement to register 600,000,000 shares of
our common stock for this facility. The registration statement was declared
effective on May 1, 2006. On September 14, 2006, we filed a registration
statement to register 260,281,228 shares of our common stock of which
175,000,000 shares were for the shares underlying the convertible debentures
held by Dutchess and 45,000,000 shares were for the shares underlying the
convertible debentures held by La Jolla. The SEC is in the process of reviewing
this filing.
The Dutchess Agreement provides that we from time to time may deliver a notice
to Dutchess that will state the dollar amount of common stock that we desire it
to purchase. The maximum amount permitted pursuant to any such notice is
$600,000, and we can give approximately three such notices per month. Upon
receipt of the notice, Dutchess is obliged to purchase the dollar amount of
common stock set forth in the notice at a purchase price equal to 96% of the
average of the two lowest closing bid prices of the common stock during the five
trading days after the notice. We are not permitted to provide a notice to
Dutchess, and Duchess is not obliged to purchase any of our shares, in the event
that we do not have sufficient authorized shares available for purchase to
fulfill such commitment. In accordance with the outstanding notes we issued to
Dutchess, we are required to use 100% of the proceeds from these puts as payment
on the notes.
On October 30, 2006, Biofrontera, AG registered its stock on the Dusseldorf and
Frankfurt, Germany stock exchanges. We anticipate that we will be able to get a
line of credit facility by using the shares we own in Biofrontera, AG as
collateral.
We have formed DNAPrint Pharmaceuticals, Inc., a wholly-owned pharmaceutical
subsidiary focused on personalized medicine. This new company will be focused on
pharmacogenomics -- personalized medicine based on a patient's DNA. To finance
our pharmacogenomics products, we will also be seeking funding for DNAPrint
Pharmaceuticals.
We do not expect our revenue stream to be sufficient to cover costs of
operations in the immediate future. We anticipate that the funding we expect to
receive from the Dutchess agreement and from borrowing funds using the shares we
own in Biofrontera, AG as collateral will fund our operating activities through
2006. We will continue to use the $35 million Dutchess facility to provide
additional cash in the future to fund future acquisitions, if any, and provide
operating cash flow. If our share price is sufficiently low, or if any number of
adverse factors or events occur, we will not have enough equity to complete
future acquisitions or possibly to continue operations beyond 2006. Management
is adequately confident that equity financing or debt will be available to fund
our operations until revenue streams are sufficient to fund operations; however,
the terms and timing of such equity or debt cannot be predicted.
We have issued securities, including our convertible debentures and our
convertible preferred stock, that are convertible into our common stock at a
continuously adjustable conversion price based on a discount on the trading
price of our common stock. In addition, our Investment Agreement with Dutchess
requires us, in order to raise capital from it, to sell our common stock to it
at a continuously adjustable conversion price at a discount to the trading price
of our common stock. As we draw down advances under the Investment Agreement
with Dutchess and more of our common stock is sold pursuant thereto, the market
price of our common stock could decrease significantly and make further advances
impractical or impossible during time periods in which we may need to raise
capital to fund our operations and market and sell our products and services. In
addition, the issuance of our common stock upon exercise or conversion of our
other securities may create a downward pressure on the market price of our
common stock.
Our consolidated financial statements are prepared using accounting principles
generally accepted in the United States of America applicable to a going
concern, which contemplate the realization of assets and liquidation of
liabilities in the normal course of business. We have incurred losses since our
inception, and have experienced and continue to experience negative cash flows
from operations. In addition, we have a working capital deficiency of $9,306,279
at September 30, 2006, and will continue to have ongoing requirements for
substantial additional capital investment to accomplish our business plan over
the next several years. Over the past few years, our operations have been funded
through related party funding, sales of common stock and preferred stock,
issuance of notes, line of credit, put notices with Dutchess and the issuance of
convertible debentures and the exercise of non-detachable warrants. We continue
to experience some success generating operating revenues, and we anticipate, but
cannot assure, that our existing funding sources will fund our operating
activities through 2006. These factors, among others, indicate that we may be
unable to continue as a going concern for a reasonable period of time.
dvshade, don't you remember how excited we were when they announced they were working on this thing called RETINOME.
Stockdope, do you have any shares left at .008? idiot.
Our competition is getting stronger
http://news.moneycentral.msn.com/ticker/article.aspx?Feed=AP&Date=20070205&ID=6439973&Sy...
Frudakis was right! They'll be lining up for our services. The world will be looking towards Hillsborough County, Fl.
$$$$$$‘Each of these programs offers us the opportunity to advance cancer treatment in a significant way,’ he said. Recent (November 2003) FDA guidance regarding pharmacogenomics technologies promulgate that if markers are validated using well understood markers in legitimate clinical environments, genetic tests derived from those markers should be included in new drug applications.
Courted?Already partnered with Moffit.eom
Looks like ADMIXMAP is the platform. $$$$$$
Don't worry stockboy I'm sure you'll be able to buy in b/w .60-.70. Too bad you don't have any cash.
Jever, just imagine if Merck re-introduces Vioxx, coupled with a DNAG statin test. You think that would make the morning news?
Remember this... Merck, the manufacturer of Vioxx pulled the
product from the market and will limit its use, if it is reintroduced, to a more
targeted group of patients, eliminating prescriptions to high risk patients.
http://72.14.209.104/search?q=cache:tN6QTYyTO14J:sec.edgar-online.com/2005/03/31/0001144204-05-00961...
There are 5000 biotech companies, but to date only 200 have launched a product. Policymakers need to address how to provide incentives that enable product development.
http://www.genome.gov/17516574
2-Zocor is a registered trademark of Merck
STATINOME is a genetic test that measures a patient’s likelihood to develop myalgia as an adverse response to the commonly prescribed Statins Lipitor¹ and Zocor²
WITH Melphalan/Topotecan THEY CAN BUILD ON THIS PATENT
http://www.freepatentsonline.com/20050101576.html
MERCK HITTING EVERBODY
WITH TAXOL, THEY HIT BRISTOL
WITH ODANSETRON THEY HIT GLAXO
http://query.nytimes.com/gst/fullpage.html?res=950DEEDF1E3AF932A25753C1A96F948260&sec=health&...
ITS ALL RIGHT THERE
BC-LOH
BC-LOH is a genetic test we are developing for mapping the relapse risk-status of normal tissue surrounding a breast tumor. The technology could help oncologists determine whether a mastectomy is warranted, and could help save many breast cancer patients from unnecessary mastectomy.
--------------------------------------------------------------------------------
BACK TO TOP
Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
--------------------------------------------------------------------------------
BACK TO TOP
Melphalan/Topotecan
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Melphalan/Topotecan (MT) response in multiple myeloma patients. MT is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting MT response could help minimize the likelihood of multiple myeloma relapse.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
--------------------------------------------------------------------------------
BACK TO TOP
Xeleri/Xelox
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Xeleri/Xelox response for colon cancer patients. Xeleri/Xelox is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting Xeleri/Xelox response could help minimize the likelihood of colon cancer relapse.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
Finally coming together. eom
PUMP THIS STOCKY
Ovanome is a genetic test for predicting an ovarian cancer patient’s response to first-regimen Taxol¹
http://www.dnaprint.com/welcome/pipeline/#OVANOME
Epothilone, which was discovered just last year by researchers at Merck to kill cells like taxol
http://www.sciencemag.org/cgi/content/full/274/5295/2009
From 1979 to 1988 Dr. Gomez was a Director and Senior Director at Merck/MSDRL Corporation. He currently serves as the Chairman of the Board of Directors of DNAPRINT genomics, Inc
http://www.zoominfo.com/people/Gomez_Hector_52657112.aspx
stockcboy
They're going to get a chunk of money from the M2GEN deal for R&D. MOFFITT affiliates will participate!!!! Atleast $100 million over the next ten years!!!!
Hence the new building.
.015 doesn't look cheap?
ann, from that article.
Access to the database, from which patients' identities have been stripped, will be given to researchers at Moffitt's affiliates, Resnick said. But others, such as faculty members at University of Florida, could apply for access for specific projects and be granted access if the request is scientifically valid, he said.
This helps all of us remember that Moffitt is the best of class in bioresearch," said Chris Steinocher, chief operating officer for Tampa Bay Partnership, a regional economic development group. "This shines the spotlight on Florida and Tampa Bay, and a lot of folks in the venture capital world and scientific world will pay attention."
I suspect we'll have access. We're getting a new building. No SK filed this month. OVANOME full steam ahead, with outside R&D funding.
Wow!! frudaky & frog are the same person.eom
stock, do you know what day of the month the journal comes out? TIA